分析子宫内膜容受性分析(ERA)对体外受精(IVF)患者胚胎移植(ET)结果的影响。PubMed,Embase,Cochrane中央控制试验登记册,和BioMedCentral数据库从开始到2022年12月进行搜索,以比较ERA和标准ET进行个性化胚胎移植(pET)的患者的妊娠结局.使用随机效应模型通过荟萃分析汇总数据。我们确定了12项研究,包括14224名患者。在活产方面,在接受ERA测试的患者和在ET之前未接受ERA测试的患者之间没有观察到差异(OR1.00,95%CI0.63-1.58,I2=92.7%),临床妊娠(OR1.20,95%CI0.90-1.61,I2=86.5%),生化妊娠(OR0.83,95%CI0.46-1.49,I2=87%),妊娠试验阳性(OR0.99,95%CI0.80-1.22,I2=0%),流产(OR0.91,95%CI0.62-1.34,I2=67.1%),和植入率(OR1.18,95%CI0.44-3.14,I2=93.2%)。与标准ET方案相比,采用ERA的pET与妊娠结局无显著差异.因此,应重新审视ERA在接受IVF的患者中的效用.
To analyze the influence of endometrial receptivity analysis (ERA) on embryo transfer (ET) results in patients undergoing in vitro fertilization (IVF) treatment. PubMed, Embase, Cochrane Central Register of Controlled Trials, and BioMed Central databases were searched from inception up to December 2022 for studies comparing pregnancy outcomes in patients undergoing personalized embryo transfer (pET) by ERA versus standard ET. Data were pooled by meta-analysis using a random effects model. We identified twelve studies, including 14,224 patients. No differences were observed between patients undergoing ERA test and those not undergoing ERA test prior to ET in terms of live birth (OR 1.00, 95% CI 0.63-1.58, I2 = 92.7%), clinical pregnancy (OR 1.20, 95% CI 0.90-1.61, I2 = 86.5%), biochemical pregnancy (OR 0.83, 95% CI 0.46-1.49, I2 = 87%), positive pregnancy test (OR 0.99, 95% CI 0.80-1.22, I2 = 0%), miscarriage (OR 0.91, 95% CI 0.62-1.34, I2 = 67.1%), and implantation rate (OR 1.18, 95% CI 0.44-3.14, I2 = 93.2%). pET with ERA is not associated with any significant differences in pregnancy outcomes as compared to standard ET protocols. Therefore, the utility of ERA in patients undergoing IVF should be revisited.